The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies.
COVID-19
Psoriasis
SARS-CoV-2
anxiety
biological therapies
depression
stress
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
pubmed:
25
7
2020
medline:
8
4
2022
entrez:
25
7
2020
Statut:
ppublish
Résumé
The beginning of 2020 has been marked by COVID-19 pandemic, with a strong impact on several national health systems worldwide. To describe the impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biologics. A telephone survey was conducted in May 4-10 2020 about the Italian lockdown period (March 9-May 3 2020) in a cohort of psoriatic patients treated with biologics, asking about any exposure to COVID-19, disease status, continuation of therapy, work activity and psychological status through Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS) and Brief Resilience Scale (BRS). 226 patients were interviewed, with no COVID-19 positive cases. Sixty-three of 226 (27.9%) described worsening of the disease with a correlation to drug withdrawal [43/226 (19%)]. Correlation was also found between the worsening of psoriasis and HADS anxiety, HADS depression, BRS and PSS abnormal scores considered both as categorical and continuous variables. No correlation was found between worsening of psoriasis and work activity. Uncertainty about whether biologics could increase the risk of SARS-CoV-2 infection led to drug withdrawal with subsequent worsening of psoriasis. Moreover, psychological status also had a direct influence on the clinical course of the disease.
Sections du résumé
BACKGROUND
BACKGROUND
The beginning of 2020 has been marked by COVID-19 pandemic, with a strong impact on several national health systems worldwide.
OBJECTIVE
OBJECTIVE
To describe the impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biologics.
METHODS
METHODS
A telephone survey was conducted in May 4-10 2020 about the Italian lockdown period (March 9-May 3 2020) in a cohort of psoriatic patients treated with biologics, asking about any exposure to COVID-19, disease status, continuation of therapy, work activity and psychological status through Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS) and Brief Resilience Scale (BRS).
RESULTS
RESULTS
226 patients were interviewed, with no COVID-19 positive cases. Sixty-three of 226 (27.9%) described worsening of the disease with a correlation to drug withdrawal [43/226 (19%)]. Correlation was also found between the worsening of psoriasis and HADS anxiety, HADS depression, BRS and PSS abnormal scores considered both as categorical and continuous variables. No correlation was found between worsening of psoriasis and work activity.
CONCLUSION
CONCLUSIONS
Uncertainty about whether biologics could increase the risk of SARS-CoV-2 infection led to drug withdrawal with subsequent worsening of psoriasis. Moreover, psychological status also had a direct influence on the clinical course of the disease.
Identifiants
pubmed: 32705945
doi: 10.1080/09546634.2020.1800578
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM